Autores
Susanne H Sheehy, Christopher JA Duncan, Sean C Elias, Katharine A Collins, Katie J Ewer, Alexandra J Spencer, Andrew R Williams, Fenella D Halstead, Samuel E Moretz, Kazutoyo Miura, Christian Epp, Matthew DJ Dicks, Ian D Poulton, Alison M Lawrie, Eleanor Berrie, Sarah Moyle, Carole A Long, Stefano Colloca, Riccardo Cortese, Sarah C Gilbert, Alfredo Nicosia, Adrian VS Hill, Simon J Draper
Fecha de publicación
2011/12/1
Revista
Molecular Therapy
Volumen
19
Número
12
Páginas
2269-2276
Editor
Nature Publishing Group
Descripción
Efficacy trials of antibody-inducing protein-in-adjuvant vaccines targeting the blood-stage Plasmodium falciparum malaria parasite have so far shown disappointing results. The induction of cell-mediated responses in conjunction with antibody responses is thought to be one alternative strategy that could achieve protective efficacy in humans. Here, we prepared chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) replication-deficient vectors encoding the well-studied P. falciparum blood-stage malaria antigen merozoite surface protein 1 (MSP1). A phase Ia clinical trial was conducted in healthy adults of a ChAd63-MVA MSP1 heterologous prime-boost immunization regime. The vaccine was safe and generally well tolerated. Fewer systemic adverse events (AEs) were observed following ChAd63 MSP1 than MVA MSP1 administration. Exceptionally strong T-cell responses were induced …
Artículos de Google Académico
SH Sheehy, CJA Duncan, SC Elias, KA Collins… - Molecular Therapy, 2011